In vitro reversible enzyme inhibition assays to predict drug-drug interactions: Current state and industry perspective from the IQ Consortium Enzyme Inhibition Working Group
Drug Metabolism and Disposition · 2026-06 · 54 (6) · 100325
DOI: 10.1016/j.dmd.2026.100325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-06. Verfasst von Carlo Sensenhauser und 16 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, Pennsylvania. Electronic address: csensenh@its.jnj.com. Hauptthemen laut MEDLINE: Drug Interactions, Enzyme Inhibitors, Drug Development. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Merck Sharp and Dohme United Kingdom.
Abstract (Originalsprache)
Inhibition of drug-metabolizing enzymes such as P450s and uridine 5'-diphosphoglucuronosyltransferase is routinely evaluated in drug discovery and development. Substantial efforts have been made over the years to standardize in vitro assay conditions and data interpretation. More recently, increasing importance has been given to the approaches for improving translation of in vitro data to predict in vivo outcomes. The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Enzyme Inhibition Working Group conducted a survey across IQ member companies to interrogate on the current state of inhibition assessment in the industry, including the strategies used as compounds progress through the pipeline, the kinetic endpoints utilized, and the accuracy of clinical drug-drug interaction predictions. Focus was also placed on how companies applied correction for unbound fraction of potential inhibitors as required by the various recent regulatory guidance documents. Results showed that most companies follow similar set-ups to identify strong inhibitors in discovery and to fully characterize drug candidates in development. Although there are some minor differences in evaluating and correcting for incubational binding, there is almost universal alignment regarding the use of kinetic endpoints with Ki = IC50/2 widely accepted to determine the inhibition constant. A majority of predictions align with clinical drug-drug interaction results, although instances of over- or underprediction were reported, and examples of these are discussed here as case studies. SIGNIFICANCE STATEMENT: Practices utilized to assess reversible inhibition of drug-metabolizing enzymes were evaluated based on 25 survey responses from IQ member companies. Results show how assay conditions, endpoints, and modeling approaches evolve as compounds advance through discovery to development. The accuracy of drug-drug interaction prediction is discussed, and recommendations for best practices are provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, Pennsylvania. Electronic address: csensenh@its.jnj.com.
- Preclinical Sciences & Translational Safety, Johnson & Johnson, San Diego, California. Electronic address: sglass3@its.jnj.com.
- Department of Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, California.
- DMPK, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut.
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Pfizer Inc, Groton, Connecticut.
- Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Förderung
- Merck Sharp and Dohme United Kingdom
Zitieren
APA
Sensenhauser, C., Glass, S. M., Dahal, U. P., Gan, G., Goosen, T. C., Hilgendorf, C., Katyayan, K., Mohutsky, M., Nørgaard, R. A., Nguyen, D., Prakash, C., Schiller, H., Shinkyo, R., Stresser, D. M., Umehara, K., Wester, M. R., & Williamson, B. (2026). In vitro reversible enzyme inhibition assays to predict drug-drug interactions: Current state and industry perspective from the IQ Consortium Enzyme Inhibition Working Group. Drug Metabolism and Disposition, 54(6), 100325. https://doi.org/10.1016/j.dmd.2026.100325
Vancouver
Sensenhauser C, Glass SM, Dahal UP, Gan G, Goosen TC, Hilgendorf C, et al. In vitro reversible enzyme inhibition assays to predict drug-drug interactions: Current state and industry perspective from the IQ Consortium Enzyme Inhibition Working Group. Drug Metabolism and Disposition. 2026;54(6):100325. doi:10.1016/j.dmd.2026.100325
BibTeX
@article{Sensenhauser2026,
author = {Sensenhauser, Carlo and Glass, Sarah M and Dahal, Upendra P and Gan, Guanfa and Goosen, Theunis C and Hilgendorf, Constanze and Katyayan, Kishore and Mohutsky, Mike and Nørgaard, Rune Aa and Nguyen, Dung and Prakash, Chandra and Schiller, Hilmar and Shinkyo, Raku and Stresser, David M and Umehara, Kenichi and Wester, Michael R and Williamson, Beth},
title = {In vitro reversible enzyme inhibition assays to predict drug-drug interactions: Current state and industry perspective from the IQ Consortium Enzyme Inhibition Working Group},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {6},
pages = {100325},
doi = {10.1016/j.dmd.2026.100325}
}
EUVIMED